Skip to Content

ValiRx - GeneICE & Cancer Research Technology Update

LONDON, Sept. 10, 2007--ValiRx (AIM: VAL), the cancer therapeutics company, is pleased to provide an update on the research programme being conducted with Cancer Research Technology Limited ("CRT"), on behalf of Cancer Research UK, on one of the proprietary GeneICE compounds developed by the Company's subsidiary, Cronos Therapeutics Ltd ("Cronos").

According to the initial results released to the Company by CRT, the GeneICE compound appears to arrest the development and terminate the existence of cancer cells, confirming earlier pre-clinical studies conducted by scientists in other research centres. The CRT studies suggested that GeneICE drug candidates targeted to Bcl-2* restored apoptosis in six cancer cell lines by penetrating the walls of cancer cells and targeting the nucleus, leading to cell death.

Dr Satu Vainikka, CEO of ValiRx, added:

"The GeneICE technology is protected from a patent position and with continued research, the relevance of the GeneICE technology to a range of cancer therapeutic applications will only increase."

Dr Jake Micallef, COO of ValiRx, commented:

"We are delighted by the latest findings which enable us and CRT to take the research activity on the GeneICE compound to its next stage of development."

--- ENDS---

Note to Editor:

* Bcl-2 is recognised as a validated key target for the development of future cancer therapies.

Information on Cancer Research Technology Limited

CRT is a specialist technology transfer company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. Further information about CRT can be found at

Information on ValiRx plc

ValiRx is a biopharmaceutical development company that is building a portfolio of complementary cancer-related therapeutic and diagnostic technologies. It currently holds stakes in Cronos and Morphogenesis Inc:

* Cronos holds licenses to two innovative and potentially market changing technologies, GeneICE and HyperGenomics; * Morphogenesis Inc. is developing a portfolio of cell therapy products for the treatment of chronic disorders. Its most advanced product, being ImmuneFx(tm) for which it recently received a patent from the US patent office.

ValiRx is headquartered in London, England. Please visit for further information.

Posted: September 2007